TEVA PHARMACEUTICAL-SP ADR (TEVA) Stock Fundamental Analysis
USA - New York Stock Exchange - NYSE:TEVA - US8816242098 - ADR
24.21 USD
-0.07 (-0.29%)
24.3 USD
+0.09 (+0.37%)
We assign a fundamental rating of 4 out of 10 to TEVA. TEVA was compared to 192 industry peers in the Pharmaceuticals industry. While TEVA is still in line with the averages on profitability rating, there are concerns on its financial health. TEVA is valued quite cheap, but it does not seem to be growing.
1. Profitability
1.1 Basic Checks
TEVA had positive earnings in the past year.
TEVA had a positive operating cash flow in the past year.
TEVA had negative earnings in 4 of the past 5 years.
TEVA had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
TEVA has a better Return On Assets (-0.39%) than 78.13% of its industry peers.
With a decent Return On Equity value of -2.31%, TEVA is doing good in the industry, outperforming 78.13% of the companies in the same industry.
Looking at the Return On Invested Capital, with a value of 10.49%, TEVA belongs to the top of the industry, outperforming 90.10% of the companies in the same industry.
TEVA had an Average Return On Invested Capital over the past 3 years of 9.12%. This is below the industry average of 13.48%.
The last Return On Invested Capital (10.49%) for TEVA is above the 3 year average (9.12%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -0.39% | ||
| ROE | -2.31% | ||
| ROIC | 10.49% |
ROA(3y)-3.67%
ROA(5y)-3.6%
ROE(3y)-23.1%
ROE(5y)-21.01%
ROIC(3y)9.12%
ROIC(5y)8.26%
1.3 Margins
TEVA's Operating Margin of 22.59% is amongst the best of the industry. TEVA outperforms 89.06% of its industry peers.
In the last couple of years the Operating Margin of TEVA has grown nicely.
The Gross Margin of TEVA (50.88%) is better than 63.54% of its industry peers.
TEVA's Gross Margin has improved in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 22.59% | ||
| PM (TTM) | N/A | ||
| GM | 50.88% |
OM growth 3Y0.25%
OM growth 5Y5.91%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.4%
GM growth 5Y2.35%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so TEVA is still creating some value.
The number of shares outstanding for TEVA has been increased compared to 1 year ago.
Compared to 5 years ago, TEVA has more shares outstanding
The debt/assets ratio for TEVA has been reduced compared to a year ago.
2.2 Solvency
TEVA has an Altman-Z score of 0.74. This is a bad value and indicates that TEVA is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of 0.74, TEVA is in line with its industry, outperforming 56.25% of the companies in the same industry.
TEVA has a debt to FCF ratio of 19.36. This is a negative value and a sign of low solvency as TEVA would need 19.36 years to pay back of all of its debts.
TEVA's Debt to FCF ratio of 19.36 is fine compared to the rest of the industry. TEVA outperforms 75.00% of its industry peers.
A Debt/Equity ratio of 2.46 is on the high side and indicates that TEVA has dependencies on debt financing.
TEVA's Debt to Equity ratio of 2.46 is on the low side compared to the rest of the industry. TEVA is outperformed by 79.17% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 2.46 | ||
| Debt/FCF | 19.36 | ||
| Altman-Z | 0.74 |
ROIC/WACC1.31
WACC7.98%
2.3 Liquidity
A Current Ratio of 1.06 indicates that TEVA should not have too much problems paying its short term obligations.
With a Current ratio value of 1.06, TEVA is not doing good in the industry: 81.25% of the companies in the same industry are doing better.
A Quick Ratio of 0.77 indicates that TEVA may have some problems paying its short term obligations.
Looking at the Quick ratio, with a value of 0.77, TEVA is doing worse than 84.90% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.06 | ||
| Quick Ratio | 0.77 |
3. Growth
3.1 Past
The earnings per share for TEVA have decreased by -3.96% in the last year.
Measured over the past years, TEVA shows a decrease in Earnings Per Share. The EPS has been decreasing by -1.18% on average per year.
Looking at the last year, TEVA shows a small growth in Revenue. The Revenue has grown by 4.40% in the last year.
The Revenue has been decreasing by -0.41% on average over the past years.
EPS 1Y (TTM)-3.96%
EPS 3Y-1.18%
EPS 5YN/A
EPS Q2Q%13.04%
Revenue 1Y (TTM)4.4%
Revenue growth 3Y1.38%
Revenue growth 5Y-0.41%
Sales Q2Q%3.42%
3.2 Future
The Earnings Per Share is expected to grow by 8.25% on average over the next years. This is quite good.
The Revenue is expected to grow by 1.77% on average over the next years.
EPS Next Y5.48%
EPS Next 2Y6.39%
EPS Next 3Y8.25%
EPS Next 5YN/A
Revenue Next Year2.79%
Revenue Next 2Y1.59%
Revenue Next 3Y1.77%
Revenue Next 5YN/A
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 8.97, the valuation of TEVA can be described as reasonable.
91.15% of the companies in the same industry are more expensive than TEVA, based on the Price/Earnings ratio.
Compared to an average S&P500 Price/Earnings ratio of 25.45, TEVA is valued rather cheaply.
TEVA is valuated reasonably with a Price/Forward Earnings ratio of 8.49.
89.06% of the companies in the same industry are more expensive than TEVA, based on the Price/Forward Earnings ratio.
TEVA is valuated cheaply when we compare the Price/Forward Earnings ratio to 34.46, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 8.97 | ||
| Fwd PE | 8.49 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of TEVA indicates a rather cheap valuation: TEVA is cheaper than 90.10% of the companies listed in the same industry.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of TEVA indicates a somewhat cheap valuation: TEVA is cheaper than 79.17% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 31.21 | ||
| EV/EBITDA | 8.98 |
4.3 Compensation for Growth
TEVA's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
TEVA has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)1.64
PEG (5Y)N/A
EPS Next 2Y6.39%
EPS Next 3Y8.25%
5. Dividend
5.1 Amount
No dividends for TEVA!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
24.21
-0.07 (-0.29%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners12.48%
Inst Owner Change-9.69%
Ins Owners0.43%
Ins Owner Change0.83%
Market Cap27.77B
Revenue(TTM)16.54B
Net Income(TTM)-158.00M
Analysts42.22
Price Target0.06 (-99.75%)
Short Float %4.49%
Short Ratio4.38
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)5.24%
Min EPS beat(2)4.65%
Max EPS beat(2)5.84%
EPS beat(4)4
Avg EPS beat(4)3.88%
Min EPS beat(4)2.01%
Max EPS beat(4)5.84%
EPS beat(8)6
Avg EPS beat(8)4.79%
EPS beat(12)7
Avg EPS beat(12)-0.36%
EPS beat(16)9
Avg EPS beat(16)-0.6%
Revenue beat(2)0
Avg Revenue beat(2)-4.72%
Min Revenue beat(2)-4.77%
Max Revenue beat(2)-4.68%
Revenue beat(4)2
Avg Revenue beat(4)-1.55%
Min Revenue beat(4)-4.77%
Max Revenue beat(4)2.63%
Revenue beat(8)5
Avg Revenue beat(8)0.64%
Revenue beat(12)6
Avg Revenue beat(12)-0.39%
Revenue beat(16)6
Avg Revenue beat(16)-1.7%
PT rev (1m)4.61%
PT rev (3m)3.61%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-4.91%
EPS NY rev (1m)0%
EPS NY rev (3m)2.84%
Revenue NQ rev (1m)-0.74%
Revenue NQ rev (3m)-1.79%
Revenue NY rev (1m)-0.25%
Revenue NY rev (3m)-1.02%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 8.97 | ||
| Fwd PE | 8.49 | ||
| P/S | 1.67 | ||
| P/FCF | 31.21 | ||
| P/OCF | 19.98 | ||
| P/B | 4.07 | ||
| P/tB | N/A | ||
| EV/EBITDA | 8.98 |
EPS(TTM)2.7
EY11.15%
EPS(NY)2.85
Fwd EY11.78%
FCF(TTM)0.78
FCFY3.2%
OCF(TTM)1.21
OCFY5%
SpS14.5
BVpS5.95
TBVpS-11.56
PEG (NY)1.64
PEG (5Y)N/A
Graham Number19.01
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -0.39% | ||
| ROE | -2.31% | ||
| ROCE | 13.29% | ||
| ROIC | 10.49% | ||
| ROICexc | 11.36% | ||
| ROICexgc | 49.13% | ||
| OM | 22.59% | ||
| PM (TTM) | N/A | ||
| GM | 50.88% | ||
| FCFM | 5.35% |
ROA(3y)-3.67%
ROA(5y)-3.6%
ROE(3y)-23.1%
ROE(5y)-21.01%
ROIC(3y)9.12%
ROIC(5y)8.26%
ROICexc(3y)10.21%
ROICexc(5y)9.09%
ROICexgc(3y)56.98%
ROICexgc(5y)49.9%
ROCE(3y)11.55%
ROCE(5y)10.49%
ROICexgc growth 3Y25.78%
ROICexgc growth 5Y17.24%
ROICexc growth 3Y15.91%
ROICexc growth 5Y18.91%
OM growth 3Y0.25%
OM growth 5Y5.91%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.4%
GM growth 5Y2.35%
F-Score6
Asset Turnover0.41
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 2.46 | ||
| Debt/FCF | 19.36 | ||
| Debt/EBITDA | 3.51 | ||
| Cap/Depr | 48.92% | ||
| Cap/Sales | 3.01% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 29.09% | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.06 | ||
| Quick Ratio | 0.77 | ||
| Altman-Z | 0.74 |
F-Score6
WACC7.98%
ROIC/WACC1.31
Cap/Depr(3y)44.85%
Cap/Depr(5y)42.78%
Cap/Sales(3y)3.33%
Cap/Sales(5y)3.4%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-3.96%
EPS 3Y-1.18%
EPS 5YN/A
EPS Q2Q%13.04%
EPS Next Y5.48%
EPS Next 2Y6.39%
EPS Next 3Y8.25%
EPS Next 5YN/A
Revenue 1Y (TTM)4.4%
Revenue growth 3Y1.38%
Revenue growth 5Y-0.41%
Sales Q2Q%3.42%
Revenue Next Year2.79%
Revenue Next 2Y1.59%
Revenue Next 3Y1.77%
Revenue Next 5YN/A
EBIT growth 1Y1.19%
EBIT growth 3Y1.63%
EBIT growth 5Y5.48%
EBIT Next Year17.17%
EBIT Next 3Y7.55%
EBIT Next 5YN/A
FCF growth 1Y-24.19%
FCF growth 3Y46.96%
FCF growth 5Y27.42%
OCF growth 1Y-18.04%
OCF growth 3Y16.04%
OCF growth 5Y10.76%
TEVA PHARMACEUTICAL-SP ADR / TEVA FAQ
What is the fundamental rating for TEVA stock?
ChartMill assigns a fundamental rating of 4 / 10 to TEVA.
What is the valuation status for TEVA stock?
ChartMill assigns a valuation rating of 7 / 10 to TEVA PHARMACEUTICAL-SP ADR (TEVA). This can be considered as Undervalued.
Can you provide the profitability details for TEVA PHARMACEUTICAL-SP ADR?
TEVA PHARMACEUTICAL-SP ADR (TEVA) has a profitability rating of 6 / 10.
What is the valuation of TEVA PHARMACEUTICAL-SP ADR based on its PE and PB ratios?
The Price/Earnings (PE) ratio for TEVA PHARMACEUTICAL-SP ADR (TEVA) is 8.97 and the Price/Book (PB) ratio is 4.07.
What is the financial health of TEVA PHARMACEUTICAL-SP ADR (TEVA) stock?
The financial health rating of TEVA PHARMACEUTICAL-SP ADR (TEVA) is 2 / 10.